Dr. Rolsma has experience in microbiology, vaccine development, and clinical research, and her current research focuses on therapeutics and interventions in critically-ill patients and clinical trials.

She is currently leading studies to evaluate the utility of therapeutic drug monitoring of beta-lactam antibiotics in critically-ill pediatric and adult patients, including patients receiving intensive cardiac support and renal replacement therapy; to evaluate the safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines in adults and children; and to evaluate the safety and immunogenicity of an intranasal influenza vaccine in children.

Dr. Rolsma also works to address vaccine safety issues as part of the CDC Clinical Immunization Safety Assessment Project.